Clinical Research Support Center

Urasoe General Hospital

Heart Failure

Stable Angina

Unstable Angina

Angina Pectoris

Stroke

Coronary Artery Disease

Atrial Fibrillation

Cough

Embolism

Acute Coronary Syndrome

glucose

Sodium

MK-7264-027

Carvedilol

MK-7264

Apixaban

Bisoprolol

Gefapixant

Bayer

Mebix

Merck Sharp & Dohme (MSD)

Juntendo University

TCROSS Co., Ltd.

condition

allSponsorName

Boehringer Ingelheim

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The EMPA-AHF trial is a multicentre, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of early initiation of once-daily oral empagliflozin 10 mg in patients hospitalized for patients with acute heart failure (AHF) who are at a high risk of adverse events.

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure

Urasoe General Hospital | Clinical Research Support Center

Site insights

Work at this site?

Active trials

Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure (EMPA-AHF)

Trial sponsors